Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial

Por van Schaik, Ivo N., van Geloven, Nan, Bril, Vera, Hartung, Hans-Peter, Lewis, Richard A., Sobue, Gen, Lawo, John-Philip, Mielke, Orell, Cornblath, David R., Merkies, Ingemar S. J.
Publicado no Trials (2016)

Efficacy and safety of Privigen® in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA stu...

Por Léger, Jean-Marc, De Bleecker, Jan L, Sommer, Claudia, Robberecht, Wim, Saarela, Mika, Kamienowski, Jerzy, Stelmasiak, Zbigniew, Mielke, Orell, Tackenberg, Björn, Shebl, Amgad, Bauhofer, Artur, Zenker, Othmar, Merkies, Ingemar S J
Publicado em 2013

Minimum clinically important difference analysis confirms the efficacy of IgPro10 in CIDP: the PRIMA trial

Por Merkies, Ingemar S. J., Lawo, John‐Philip, Edelman, Jonathan M., De Bleecker, Jan L., Sommer, Claudia, Robberecht, Wim, Saarela, Mika, Kamienowski, Jerzy, Stelmasiak, Zbigniew, Mielke, Orell, Tackenberg, Björn, Léger, Jean‐Marc
Publicado no J Peripher Nerv Syst (2017)